Back Back
Cell No. : Cell Name
RCB2227 : JMSU1  update : 2023/10/16
CommentHuman cell line derived from urinary bladder carcinoma. Derived from ascites.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Morita, Tasuo
Originator Morita, Tatsuo
Year of deposit 2002
Another name HMSU-1
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 75 years
Tissue bladder, ascites meta
Disease name urinary bladder carcinoma
Metastatic ability Yes
Metastatic tissue lung, liver, bone marrow, lympho node, peritoneum
Classification cancer
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_2081
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 4

To topTop

To topTop
User's Publication
21582  Schönherr H, Ayaz P, Taylor AM, Casaletto JB, Touré BB, Moustakas DT, Hudson BM, Valverde R, Zhao S, O'Hearn PJ, Foster L, Sharon DA, Garfinkle S, Giordanetto F, Lescarbeau A, Kurukulasuriya R, Gerami-Moayed N, Maglic D, Bruderek K, Naik G, Gunaydin H, Mader MM, Boezio AA, McLean TH, Chen R, Wang Y, Shaw DE, Watters J, Bergstrom DA.  Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.  Proc Natl Acad Sci U S A  2024  121(6):e2317756121  PubMed ID: 38300868   DOI: 10.1073/pnas.2317756121
21362  Ando K, Kurashina R, Motoi N, Iizuka T, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y.  Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.  Biochem Biophys Res Commun  2023  676:165-170  PubMed ID: 37517219   DOI: 10.1016/j.bbrc.2023.07.054
17934  Ohtsu A, Arai S, Sawada T, Kato M, Maeno Y, Miyazawa Y, Fujizuka Y, Sekine Y, Koike H, Matsui H, Suzuki K.  Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells  Biochem Biophys Res Commun  2022  628:76-83  PubMed ID: 36084554   DOI: 10.1016/j.bbrc.2022.08.083
14224  Aya Kikuchi, Tomoyuki Suzuki, Taisuke Nakazawa, Masateru Iizuka, Ayako Nakayama, Tohru Ozawa, Minoru Kameda, Nobuaki Shindoh, Tadashi Terasaka, Masaaki Hirano, Sadao Kuromitsu  ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance  Cancer Science  2017  108:236-242  PubMed ID: 27885740   DOI: 10.1111/cas.13124

Back Back Return Top Page